Universities Are Making Billions Gatekeeping Your Meds

Research universities, many of them public, have joined forces with pharmaceutical companies and Wall Street firms to fight new government efforts to curtail out-of-control drug prices, saying the regulations could stifle innovation.

But these universities are also likely concerned that drug-price reforms would hamper their profits. Case in point: the University of California, Los Angeles (UCLA) has quietly reaped more than a billion dollars in payouts from Xtandi, a lifesaving cancer drug that it developed with the help of government funding and now costs U.S. patients $200,000 a year.